Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Amarantus BioScience Holdings, Inc. (AMBS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0030-0.0001 (-3.23%)
At close: 02:22PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0031
Open0.0030
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0027 - 0.0033
52 Week Range0.0018 - 0.0185
Volume702,634
Avg. Volume1,215,223
Market Cap2.417M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AMBS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AMARANTUS BIOSCIENCE HLDGS INC
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more
Advertisement
Advertisement